Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer

Journal of Clinical Oncology

Volumn 12, Issue 11, 1994, Pages 2301-2308

  Francis, Prudence ^a   Schneider, Jeffrey ^a,b   Kann, Lucy ^a   Balmaceda, Casilda ^a   Barakat, Richard ^a   Phillips, Mary ^a   Hakes, Thomas ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CORTICOSTEROID; DIPHENHYDRAMINE; DOCETAXEL; PLATINUM DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; EDEMA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH;

EID: 0027999654     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1994.12.11.2301     Document Type: Article

References (27)

1. McGuire WP, Rowinsky EK, Rosenhein NB, et al: Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273-279, 1989
2. Thigpen T, Blessing J, Ball H, et al: Phase II trial of Taxol as second-line therapy for ovarian carcinoma: A Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 9:156, 1990 (abstr 604)
3. Einzig A, Wiernik P, Sasloff J, et al: Phase II study and long term follow up of patients treated with Taxol for advanced ovarian adenocarcinoma. J Clin Oncol 10:1748-1753, 1992
4. Sarosy G, Kohn E, Stone DA, et al: Phase I study of Taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 10:1165-1170, 1992
5. Sarosy G, Kohn E, Link C, et al: Taxol dose intensification in patients with recurrent ovarian cancer. Proc Am Soc Clin Oncol 11:226, 1992 (abstr 716)
6. Denis JN, Greene AE, Guenard D, et al: A highly efficient practical approach to natural Taxol. J Am Chem Soc 110:5917-5919, 1988
7. Mangatal L, Adeline MT, Guenard D, et al: Application of the vicinal oxyamination reaction with asymmetric induction to the hemisynthesis of Taxol and analogues. Tetrahedron 45:4177-4190, 1989
8. Bissery M, Guenard D, Gueritte-Voegelein F, et al: Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a Taxol analogue. Cancer Res 51:4845-4852, 1991
9. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by Taxol. Nature 277:665-667, 1979
10. Gueritte-Voegelein F, Guenard D, Lavelle F, et al: Relationships between the structure of Taxol analogues and their antimitotic activity. J Med Chem 34:992-998, 1991
11. Ringel I, Horwitz SB: Studies with RP 56976 (Taxotere): A semisynthetic analogue of Taxol. J Natl Cancer Inst 83:288-291, 1991
12. Kelland LR, Abel G: Comparative in vitro cytotoxicity of Taxol and Taxotere against cisplatin-sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 30:444-450, 1992
13. Harrison SD, Dykes DJ, Shepherd RV, et al: Responses of human tumor xenografts to Taxotere. Proc Am Assoc Cancer Res 33:526, 1992 (abstr 3144)
14. Extra J, Rousseau F, Bruno R, et al: Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 53:1037-1042, 1993
15. Bissett D, Setanoians A, Cassidy J, et al: Phase I and pharmacokinetic study of Taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 53:523-527, 1993
16. Pazdur R, Newman RA, Newman BM, et al: Phase I trial of Taxotere: Five-day schedule. J Natl Cancer Inst 84:1781-1781, 1992
17. Bums H, Irvin R, Kuhn J, et al: Phase I clinical trial of Taxotere given either as a 2-hour or a 6-hour intravenous infusion. J Clin Oncol 11:950-958, 1993
18. DeValeriola D, Brassinne C, Picart M, et al: Phase I pharmacokinetic study of Taxotere (RP 56976) administered as a weekly infusion. Proc Am Assoc Cancer Res 33:261, 1992 (abstr 1563)
19. Kavanagh J, Kudelka A, Freedman R, et al: Taxotere (Docetaxel): Activity in platin refractory ovarian cancer and amelioration of toxicity. Proc Am Soc Clin Oncol 13:237, 1994 (abstr 732)
20. Aapro M, Pujade-Lauraine E, Lhomme C, et al: Phase II study of Taxotere in ovarian cancer. Proc Am Soc Clin Oncol 12:256, 1993 (abstr 809)
21. Piccart MJ, Gore M, Ten Bokkel Huinink W, et al: Taxotere (RP56976, NSC628503): An active new drug for the treatment of advanced ovarian cancer. Proc Am Soc Clin Oncol 12:258, 1993 (abstr 820)
22. Francis PA, Rigas JR, Kris MG, et al: Phase II trial of docetaxel (Taxotere) in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 12:1232-1237, 1994
23. Rodriguez MA, Swan F, Hagenester F, et al: High-dose ESHAP with GM-CSF vs prophylactic antibiotics. Blood 76:370, 1990 (suppl 1, abstr)
24. Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164-170, 1991
25. Rhône-Poulenc Rorer: Investigator's Brochure RP56976. International Registration Department. Antony, France, March, 1992
26. Galindo E, Kavanagh J, Fossella F, et al: Docetaxel (Taxotere) toxicities: An analysis of single institution experience of 168 patients (623 courses). Proc Am Soc Clin Oncol 14:164, 1994 (abstr 452)
27. Oulid-Aïssa D, Béhar A, Spielmann M, et al: Management of fluid retention syndrome in patients treated with Taxotere (docetaxel): Effect of premedication. Proc Am Soc Clin Oncol 14:465, 1994 (abstr 1614)